GlaxoSmithKline plc Share Price LIQUIDNET SYSTEMS
Stocks
GSK
GB0009252882
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.40% | - |
| 06-18 | Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine |  |
| 06-18 | The Gulf Gives, the Fed Takes | |
| Market Cap | 76.77B 102B 88.53B 81.61B 144B 9,576B 145B 971B 377B 4,719B 381B 373B 16,357B | P/E 2026 * |
12.3x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 91.76B 121B 106B 97.56B 172B 11,448B 173B 1,161B 451B 5,641B 456B 446B 19,554B | EV / Sales 2026 * |
2.72x | EV / Sales 2027 * | 2.5x |
| Free-Float |
92.29% | Yield 2026 * |
3.74% | Yield 2027 * | 3.96% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 31/12/2025 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 30/04/2023 |
| Chief Tech/Sci/R&D Officer | - | 30/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 05/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 31/12/2017 |
Jonathan Symonds
CHM | Chairman | 68 | 31/08/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.40% | - | - | 102B | |
| -1.21% | -5.37% | +39.94% | +145.38% | 980B | |
| -2.48% | -4.17% | +51.52% | +39.07% | 550B | |
| -2.14% | -3.68% | +16.71% | +56.15% | 382B | |
| -1.18% | +0.25% | +25.86% | +16.53% | 317B | |
| -2.36% | -3.12% | +24.71% | +11.59% | 270B | |
| -2.45% | -2.88% | +24.29% | +30.06% | 269B | |
| -1.91% | -0.87% | -41.95% | -49.25% | 191B | |
| -1.19% | -4.65% | +16.56% | +47.00% | 182B | |
| -1.35% | -1.68% | +14.59% | +56.94% | 154B | |
| Average | -1.63% | -2.68% | +19.14% | +39.27% | 366B | |
| Weighted average by Cap. | -1.72% | -3.38% | +28.08% | +63.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.79B 44.73B 38.97B 35.93B 63.22B 4,216B 63.67B 427B 166B 2,078B 168B 164B 7,201B | 35.48B 46.96B 40.92B 37.72B 66.37B 4,426B 66.84B 449B 174B 2,181B 176B 172B 7,560B |
| Net income | 6.27B 8.29B 7.23B 6.66B 11.72B 782B 11.81B 79.26B 30.78B 385B 31.13B 30.47B 1,335B | 6.67B 8.83B 7.69B 7.09B 12.48B 832B 12.56B 84.36B 32.76B 410B 33.14B 32.43B 1,421B |
| Net Debt | 15B 19.85B 17.3B 15.95B 28.06B 1,871B 28.26B 190B 73.68B 922B 74.52B 72.92B 3,196B | 11.93B 15.8B 13.76B 12.69B 22.33B 1,489B 22.48B 151B 58.63B 734B 59.3B 58.03B 2,543B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
